Sangamo Therapeutics (SGMO) Misses Q4 EPS by 1c
Tweet
Share
E-mailGet Alerts SGMO Hot Sheet
Join SI Premium – FREE
Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $7.55 million versus the consensus estimate of $10.32 million.
For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Reiterates Outperform Rating on Southwest (LUV)
- Asana, Inc. (ASAN) Tops Q2 EPS by 1c; offers guidance
- Asana shares tumble on weak third quarter earnings outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
